J&J(US:JNJ) Huan Qiu Wang Zi Xun·2025-11-10 10:38Core Insights - The 8th China International Import Expo has opened in Shanghai, with Johnson & Johnson showcasing its commitment to addressing global health challenges through innovative medical technologies [1][2] - Johnson & Johnson's latest pulse field ablation (PFA) solutions have garnered significant attention, including the debut of the OMNYPULSE catheter, which quantifies ablation damage depth and provides real-time pressure monitoring [1] - The VARIPULSE catheter, launched in April, has already served over 2,000 patients, demonstrating its potential in treating atrial fibrillation [1] Group 1 - Johnson & Johnson emphasizes its comprehensive strength across medical technology and innovative pharmaceuticals at the expo [1] - The company aims to introduce a new PFA product to the Chinese market annually, enhancing atrial fibrillation treatment standards [2] - The DESTSF catheter combines radiofrequency and pulse energy, showcasing advanced capabilities in real-time pressure and ablation index monitoring [1] Group 2 - The immersive "healing space" created by Johnson & Johnson at the expo highlights its dedication to innovation in healthcare [1] - The introduction of the OMNYPULSE catheter marks a significant advancement in the field of pulse ablation technology [1] - Johnson & Johnson's ongoing commitment to innovation is reflected in its strategic focus on the Chinese market [2]